Endometrial cancer
Not yet recruitingMaintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer
Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer
- Disease:Endometrial cancer
- Substances:DostarlimabGSK5733584+1
France- Participants:18–64 years · 65+ years
- Substances:Dostarlimab
- Sponsor:Glaxosmithkline Research & Development Limited










